Clinical trial NCT01397513 - References

Diabetes Mellitus, Type 1 — Effects of Aspirin Treatment on Fibrin Network Formation in Patients With Type 1 Diabetes

Citation(s)

•   Antovic A, Perneby C, Ekman GJ, Wallen HN, Hjemdahl P, Blombäck M, He S
  Marked increase of fibrin gel permeability with very low dose ASA treatment. Thromb Res. 2005;116(6):509-17.
•   Ardawi MS, Nasrat HN, Mira SA, Fatani HH
  Comparison of glycosylated fibrinogen, albumin, and haemoglobin as indices of blood glucose control in diabetic patients. Diabet Med. 1990 Nov;7(9):819-24.
•   Bjornsson TD, Schneider DE, Berger H Jr
  Aspirin acetylates fibrinogen and enhances fibrinolysis. Fibrinolytic effect is independent of changes in plasminogen activator levels. J Pharmacol Exp Ther. 1989 Jul;250(1):154-61.
•   Colle JP, Mishal Z, Lesty C, Mirshahi M, Peyne J, Baumelou A, Bensman A, Soria J, Soria C
  Abnormal fibrin clot architecture in nephrotic patients is related to hypofibrinolysis: influence of plasma biochemical modifications: a possible mechanism for the high thrombotic tendency? Thromb Haemost. 1999 Nov;82(5):1482-9.
•   Collet JP, Allali Y, Lesty C, Tanguy ML, Silvain J, Ankri A, Blanchet B, Dumaine R, Gianetti J, Payot L, Weisel JW, Montalescot G
  Altered fibrin architecture is associated with hypofibrinolysis and premature coronary atherothrombosis. Arterioscler Thromb Vasc Biol. 2006 Nov;26(11):2567-73. Epub 2006 Aug 17.
•   Collet JP, Park D, Lesty C, Soria J, Soria C, Montalescot G, Weisel JW
  Influence of fibrin network conformation and fibrin fiber diameter on fibrinolysis speed: dynamic and structural approaches by confocal microscopy. Arterioscler Thromb Vasc Biol. 2000 May;20(5):1354-61.
•   Cubbon RM, Gale CP, Rajwani A, Abbas A, Morrell C, Das R, Barth JH, Grant PJ, Kearney MT, Hall AS
  Aspirin and mortality in patients with diabetes sustaining acute coronary syndrome. Diabetes Care. 2008 Feb;31(2):363-5. Epub 2007 Oct 24.
•   Dunn EJ, Philippou H, Ariëns RA, Grant PJ
  Molecular mechanisms involved in the resistance of fibrin to clot lysis by plasmin in subjects with type 2 diabetes mellitus. Diabetologia. 2006 May;49(5):1071-80. Epub 2006 Mar 16.
•   Ganda OP, Arkin CF
  Hyperfibrinogenemia. An important risk factor for vascular complications in diabetes. Diabetes Care. 1992 Oct;15(10):1245-50.
•   Jörneskog G, Egberg N, Fagrell B, Fatah K, Hessel B, Johnsson H, Brismar K, Blombäck M
  Altered properties of the fibrin gel structure in patients with IDDM. Diabetologia. 1996 Dec;39(12):1519-23.
•   Lütjens A, te Velde AA, vd Veen EA, vd Meer J
  Glycosylation of human fibrinogen in vivo. Diabetologia. 1985 Feb;28(2):87-9.
•   Nomura S, Suzuki M, Katsura K, Xie GL, Miyazaki Y, Miyake T, Kido H, Kagawa H, Fukuhara S
  Platelet-derived microparticles may influence the development of atherosclerosis in diabetes mellitus. Atherosclerosis. 1995 Aug;116(2):235-40.
•   Rooth E, Wallen NH, Blombäck M, He S
  Decreased fibrin network permeability and impaired fibrinolysis in the acute and convalescent phase of ischemic stroke. Thromb Res. 2011 Jan;127(1):51-6. doi: 10.1016/j.thromres.2010.09.011. Epub 2010 Oct 14.
•   Siljander P, Carpen O, Lassila R
  Platelet-derived microparticles associate with fibrin during thrombosis. Blood. 1996 Jun 1;87(11):4651-63.
•   Tehrani S, Mobarrez F, Antovic A, Santesson P, Lins PE, Adamson U, Henriksson P, Wallén NH, Jörneskog G
  Atorvastatin has antithrombotic effects in patients with type 1 diabetes and dyslipidemia. Thromb Res. 2010 Sep;126(3):e225-31. doi: 10.1016/j.thromres.2010.05.023. Epub 2010 Jul 15.
•   Undas A, Brummel-Ziedins KE, Mann KG
  Antithrombotic properties of aspirin and resistance to aspirin: beyond strictly antiplatelet actions. Blood. 2007 Mar 15;109(6):2285-92. Epub 2006 Dec 5. Review.
•   Williams S, Fatah K, Hjemdahl P, Blombäck M
  Better increase in fibrin gel porosity by low dose than intermediate dose acetylsalicylic acid. Eur Heart J. 1998 Nov;19(11):1666-72.
•   Yngen M, Ostenson CG, Hu H, Li N, Hjemdahl P, Wallén NH
  Enhanced P-selectin expression and increased soluble CD40 Ligand in patients with Type 1 diabetes mellitus and microangiopathy: evidence for platelet hyperactivity and chronic inflammation. Diabetologia. 2004 Mar;47(3):537-40. Epub 2004 Feb 13.

Effects of Low and High Doses of Aspirin Treatment on Fibrin Network Formation in Patients With Type 1 Diabetes and Possible Influence of the Glycemic Control.

Details for clinical trial NCT01397513